StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VRDNBullishAnalyst Target Updateanalyst
Medium materiality5/10

BofA Starts Viridian Therapeutics at Buy

Nov 19, 2026, 10:07 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The positive initiation and meaningful target gap are bullish, but the view is based on one analyst's assessment.

AI summary

What happened, with direct paths to the underlying reporting

Bank of America initiated coverage of Viridian Therapeutics with a Buy rating and a $47 target versus a posted price of $30.12.

  • Analyst target: $47; posted price: $30.12.
  • Price change since signal: +2.36%.

Key facts

  1. 01

    Target: $47

  2. 02

    Posted price: $30.12

  3. 03

    Analyst firm: Bank of America Securities

  4. 04

    Analyst: Daniel Giraldo

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.